• PN: B311185


45x Ab-conjugated beads (S4P5 - Rat IL-5 Ab-bead). PN: B311185A. One vial containing 100 µL of anti-rat IL-5 conjugated to AimPlex Bead S4P5.

25x Biotin-detection Ab (Rat IL-5 Biotin-dAb). PN: B311185B. One vial containing 100 µL of biotinylated anti-rat IL-5.

Lyophilized Standard Mix - Rat Group 1 Panel B, 12-Plex. PN: RG10012. One vial containing lyophilized recombinant rat Eotaxin, G-CSF, GM-CSF, IL-1α, IL-1β, IL-5, IL-12p70, IL-13, KC, IP-10, and MIP-1α, MIP-2.  Note: If multiple analyte kits on the above target list are ordered as a panel, only one vial of standard mix is supplied for those analyte kits

STORAGE:  2-8 C in the dark.

IMPORTANT: Sodium azide forms explosive compounds with heavy metals. These products contain <0.05% (w/w) azide which with repeated contact with lead and copper commonly found in plumbing drains may result in the buildup of shock sensitive compounds. Dispose in accordance with regulations from your institute.

APPLICATION: Optimal antibody pair and antigen standard for assaying Rat IL-5. Can be multiplexed with other analytes in Rat Group 1. To be used in conjunction with the AimPlex Mouse/Rat Basic Kit (PN: P200201) and a diluent kit. Refer to the AimPlex Multiplex Immunoassay User Manual and kit inserts for the assay procedure.

For Research Use Only.  Not for use in diagnostic procedures.

Assay Specifications:

Sample types: Cell culture supernatant, serum, plasma, bodily fluid and tissue/cell lysate

Sensitivity (LOD): < 2 pg/mL

Quantitation range:

LLOQ: < 5 pg/mL

ULOQ: > 5,000 pg/mL

Standard dose recovery: 70-130%

Intra-assay CV: < 10%

Inter-assay CV: < 20%

Cross-reactivity of analytes in Rat Group 1: Negligible

Sample volume: 15 µL/test


Interleukin 5 (Accession Q08125) or Eosinophil Differentiation Factor (EDF) is produced by both hematopoietic and non-hematopoietic cells such as T cells and granulocytes. IL-5, along with IL-3, and GM-CSF are mediators for eosinophil differentiation, though IL-5 has an eosinophil specificity and plays a role in their maturation. Overexpression of IL-5 in vivo increases amounts of B cells (mostly in mice), eosinophils (in humans), and antibodies significantly. Targeting IL-5 expression may have implications for such conditions as food allergies, asthma, inflammatory bowel diseases, and drug hypersensitivity.


  1. Kiyoshi T, Nakajima H. IL-5 and Eosinophila.

  2. Kouro T, Takatsu K. IL-5-and eosinophil-mediated inflammation: from discovery to therapy. Int. Immunol. 2009. Dec 21(12): 1303-9. Doi:10.1093/intimm/dxp102. PMID: 19819937.

  3. Sanderson CJ. Eosinophil Differentiation Factor (Interleukin-5). Immunol Ser. 1990; 49:231-56. PMID: 2090253.

  4. Takatsu K. Interleukin-5 and IL-5 Receptor in Health and Diseases. Proc Jpn Acad Ser B Phys Biol Sci. 2011; 87(8): 463-85. Doi: 10.2183/pjab.87.463. PMID: 21986312.

  5. Yanagibashi T, Satoh M, Nagai Y, Koike M, Takatsu K. Allergic diseases: From bench to clinic – Contribution of the discovery of interleukin-5. Cytokine. 2017 Oct; 98:59-70. Doi:10.1016/j.cyto.2016.11.011.